Thyroid eye disease with dysthyroid optic neuropathy 15 years after incomplete thyroidectomy. [PDF]
Bytyqi F +4 more
europepmc +1 more source
Thyroid-Associated Orbitopathy: Who and How to Treat
Thyroid-associated orbitopathy is the most frequent and troublesome nonthyroidal complication of Graves\u27 disease. It is mandatory to determine whether sight-threatening orbitopathy is present, as this requires prompt and aggressive treatment ...
Dickinson J, Perros P
core +1 more source
Thyroid Eye Disease in the Teprotumumab Era: Pathophysiology, Clinical Activity Assessment, and an Updated Therapeutic Landscape. [PDF]
Shooshani T +3 more
europepmc +1 more source
Orbital Radiotherapy for Thyroid-Associated Orbitopathy in the Era of Targeted Biologics: Reposition, Not Replace. [PDF]
Jo JH, Seol KH.
europepmc +1 more source
Tocilizumab in refractory pretibial myxedema: new therapeutic insights. [PDF]
Corrias S +5 more
europepmc +1 more source
<i>In vitro</i> evaluation of the interaction between orbital fibroblasts and PBMCs from Graves' orbitopathy patients in triggering periorbital remodeling. [PDF]
Starosz A +6 more
europepmc +1 more source
Thyroid Eye Disease in the Teprotumumab Era: A Narrative Review of Expanding the Therapeutic Window Beyond Disease Activity. [PDF]
Sirang Z, Khan R, Moazzum W, Jeeva I.
europepmc +1 more source
Combined Orbital Decompression and Rectus Muscle Myectomy for Large-Angle Strabismus in Thyroid-Associated Orbitopathy. [PDF]
Hsieh MW +5 more
europepmc +1 more source
WSOPRAS and ITEDS Consensus Statement on the Assessment and Management of Thyroid Eye Disease. [PDF]
Kossler AL +5 more
europepmc +1 more source
Health-related quality of life in benign thyroid diseases assessed by ThyPRO. [PDF]
Sawicka-Gutaj N +9 more
europepmc +1 more source

